8.38 USD
-0.11 (-1.3%)
8.31 USD
-0.07 (-0.84%)
Taking everything into account, ZVRA scores 4 out of 10 in our fundamental rating. ZVRA was compared to 190 industry peers in the Pharmaceuticals industry. ZVRA has a bad profitability rating. Also its financial health evaluation is rather negative. ZVRA is growing strongly while it is still valued neutral. This is a good combination!
1. Profitability
1.1 Basic Checks
In the past year ZVRA was profitable.
ZVRA had a negative operating cash flow in the past year.
In the past 5 years ZVRA always reported negative net income.
In the past 5 years ZVRA reported 4 times negative operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 13.08%, ZVRA belongs to the best of the industry, outperforming 93.68% of the companies in the same industry.
ZVRA has a better Return On Equity (26.53%) than 93.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.08% | ||
| ROE | 26.53% | ||
| ROIC | N/A |
ROA(3y)-40.64%
ROA(5y)-56.64%
ROE(3y)-129.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ZVRA has a better Profit Margin (41.86%) than 97.37% of its industry peers.
Looking at the Gross Margin, with a value of 93.88%, ZVRA belongs to the top of the industry, outperforming 95.26% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 41.86% | ||
| GM | 93.88% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ZVRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ZVRA has been increased compared to 1 year ago.
ZVRA has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ZVRA has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 0.69, we must say that ZVRA is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.69, ZVRA is in line with its industry, outperforming 50.00% of the companies in the same industry.
A Debt/Equity ratio of 0.46 indicates that ZVRA is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.46, ZVRA is not doing good in the industry: 62.11% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.69 |
ROIC/WACCN/A
WACC9.66%
2.3 Liquidity
ZVRA has a Current Ratio of 8.62. This indicates that ZVRA is financially healthy and has no problem in meeting its short term obligations.
ZVRA has a Current ratio of 8.62. This is in the better half of the industry: ZVRA outperforms 75.26% of its industry peers.
A Quick Ratio of 8.57 indicates that ZVRA has no problem at all paying its short term obligations.
ZVRA has a better Quick ratio (8.57) than 75.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.62 | ||
| Quick Ratio | 8.57 |
3. Growth
3.1 Past
ZVRA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 122.84%, which is quite impressive.
ZVRA shows a strong growth in Revenue. In the last year, the Revenue has grown by 240.47%.
ZVRA shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.96% yearly.
EPS 1Y (TTM)122.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.55%
Revenue 1Y (TTM)240.47%
Revenue growth 3Y-6.24%
Revenue growth 5Y12.96%
Sales Q2Q%605.36%
3.2 Future
ZVRA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.20% yearly.
The Revenue is expected to grow by 76.65% on average over the next years. This is a very strong growth
EPS Next Y157.77%
EPS Next 2Y50.05%
EPS Next 3Y39.67%
EPS Next 5Y28.2%
Revenue Next Year388.89%
Revenue Next 2Y165.06%
Revenue Next 3Y121.31%
Revenue Next 5Y76.65%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 18.62 indicates a rather expensive valuation of ZVRA.
82.11% of the companies in the same industry are more expensive than ZVRA, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 27.25. ZVRA is valued slightly cheaper when compared to this.
With a Price/Forward Earnings ratio of 14.74, ZVRA is valued correctly.
Based on the Price/Forward Earnings ratio, ZVRA is valued cheaply inside the industry as 82.63% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.98, ZVRA is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.62 | ||
| Fwd PE | 14.74 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ZVRA's earnings are expected to grow with 39.67% in the coming years.
PEG (NY)0.12
PEG (5Y)N/A
EPS Next 2Y50.05%
EPS Next 3Y39.67%
5. Dividend
5.1 Amount
ZVRA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
8.38
-0.11 (-1.3%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners70.03%
Inst Owner ChangeN/A
Ins Owners0.69%
Ins Owner Change9.95%
Market Cap471.79M
Revenue(TTM)84.39M
Net Income(TTM)35.33M
Analysts84.29
Price Target23.31 (178.16%)
Short Float %12.54%
Short Ratio5.55
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)25.59%
Min EPS beat(2)-20.8%
Max EPS beat(2)71.99%
EPS beat(4)2
Avg EPS beat(4)13.08%
Min EPS beat(4)-67.34%
Max EPS beat(4)71.99%
EPS beat(8)3
Avg EPS beat(8)-5.61%
EPS beat(12)4
Avg EPS beat(12)-9.16%
EPS beat(16)5
Avg EPS beat(16)-12.64%
Revenue beat(2)1
Avg Revenue beat(2)4.28%
Min Revenue beat(2)-4.04%
Max Revenue beat(2)12.59%
Revenue beat(4)3
Avg Revenue beat(4)14.7%
Min Revenue beat(4)-4.04%
Max Revenue beat(4)32.28%
Revenue beat(8)5
Avg Revenue beat(8)4.12%
Revenue beat(12)7
Avg Revenue beat(12)14.01%
Revenue beat(16)9
Avg Revenue beat(16)10.43%
PT rev (1m)0%
PT rev (3m)-4.76%
EPS NQ rev (1m)0%
EPS NQ rev (3m)278.95%
EPS NY rev (1m)0%
EPS NY rev (3m)6.44%
Revenue NQ rev (1m)-0.01%
Revenue NQ rev (3m)-0.2%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.73%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.62 | ||
| Fwd PE | 14.74 | ||
| P/S | 5.59 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.54 | ||
| P/tB | 3.88 | ||
| EV/EBITDA | N/A |
EPS(TTM)0.45
EY5.37%
EPS(NY)0.57
Fwd EY6.79%
FCF(TTM)-0.54
FCFYN/A
OCF(TTM)-0.41
OCFYN/A
SpS1.5
BVpS2.37
TBVpS2.16
PEG (NY)0.12
PEG (5Y)N/A
Graham Number4.89
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.08% | ||
| ROE | 26.53% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 41.86% | ||
| GM | 93.88% | ||
| FCFM | N/A |
ROA(3y)-40.64%
ROA(5y)-56.64%
ROE(3y)-129.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.31
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 128.58% | ||
| Cap/Sales | 8.14% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.62 | ||
| Quick Ratio | 8.57 | ||
| Altman-Z | 0.69 |
F-Score6
WACC9.66%
ROIC/WACCN/A
Cap/Depr(3y)44.3%
Cap/Depr(5y)36.5%
Cap/Sales(3y)9.12%
Cap/Sales(5y)5.58%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)122.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.55%
EPS Next Y157.77%
EPS Next 2Y50.05%
EPS Next 3Y39.67%
EPS Next 5Y28.2%
Revenue 1Y (TTM)240.47%
Revenue growth 3Y-6.24%
Revenue growth 5Y12.96%
Sales Q2Q%605.36%
Revenue Next Year388.89%
Revenue Next 2Y165.06%
Revenue Next 3Y121.31%
Revenue Next 5Y76.65%
EBIT growth 1Y66.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year19.53%
EBIT Next 3Y40.04%
EBIT Next 5Y32.31%
FCF growth 1Y-36.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-6.98%
OCF growth 3YN/A
OCF growth 5YN/A
ZEVRA THERAPEUTICS INC / ZVRA FAQ
What is the fundamental rating for ZVRA stock?
ChartMill assigns a fundamental rating of 4 / 10 to ZVRA.
What is the valuation status for ZVRA stock?
ChartMill assigns a valuation rating of 5 / 10 to ZEVRA THERAPEUTICS INC (ZVRA). This can be considered as Fairly Valued.
What is the profitability of ZVRA stock?
ZEVRA THERAPEUTICS INC (ZVRA) has a profitability rating of 3 / 10.
What is the earnings growth outlook for ZEVRA THERAPEUTICS INC?
The Earnings per Share (EPS) of ZEVRA THERAPEUTICS INC (ZVRA) is expected to grow by 157.77% in the next year.